A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.

Arch Drug Inf · 2008 · PMC2817438 · PMID 20157362

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Also in the etoricoxib group, CRP decreased 50.8% (95% CI: −81.7, 32.5) below placebo among diabetic patients and 31.9% (95% CI: −55.0, 3.1) below placebo in individuals with higher than median Framingham risk scores; while these treatment differences were noteworthy, they did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.